High-grade gliomas, including glioblastomas, are malignant brain tumors for which improved treatment is urgently needed. Genetic studies have demonstrated the existence of biologically distinct subsets. Preliminary studies have indicated that platelet-derived growth factor (PDGF) receptor signaling contributes to the growth of some of these tumors. In this study, human high-grade glioma primary cultures were analysed for sensitivity to treatment with the PDGF receptor inhibitor imatinib/ Glivec/Gleevec/STI571. Six out of 15 cultures displayed more than 40% growth inhibition after imatinib treatment, whereas seven cultures showed less than 20% growth inhibition. In the sensitive cultures, apoptosis contributed to growth inhibition. Platelet-derived growth factor receptor status correlated with imatinib sensitivity. Supervised analyses of gene expression profiles and real-time PCR analyses identified expression of the chemokine CXCL12/SDF-1 (stromal cell-derived factor 1) as a predictor of imatinib sensitivity. Exogenous addition of CXCL12 to imatinib-insensitive cultures conferred some imatinib sensitivity. Finally, coregulation of CXCL12 and PDGF a-receptor was observed in glioblastoma biopsies. We have thus defined the characteristics of a novel imatinib-sensitive subset of glioma cultures, and provided evidence for a functional relationship between imatinib sensitivity and chemokine signaling. These findings will assist in the design and evaluation of clinical trials exploring therapeutic effects of imatinib on malignant brain tumors.
Introduction
High-grade gliomas are the most common malignant brain tumor of the adult. Treatment is presently based on a combination of surgery, radiation therapy and chemotherapy. However, with these treatment modalities, responses are extremely poor. A recent population-based analysis of glioblastoma reported 17.7% 1-year survival and 3.3% 2-year survival (Ohgaki et al., 2004) . Identification of novel treatment strategies is therefore highly warranted.
Glioblastoma has been broadly divided into primary and secondary glioblastomas (Kleihues et al., 2002) . Secondary glioblastomas progress from lower grade gliomas, and also occur more frequently in younger patients, whereas primary glioblastomas appear de novo. Primary glioblastomas are characterized by amplification of an often mutated epidermal growth factor (EGFR) gene, whereas secondary glioblastomas are associated with p53 mutations and overexpression of Platelet derived growth factor (PDGF) and PDGF receptors. Recent studies have identified a novel subset among the secondary glioblastomas characterized by overexpression of genes on chromosome 12q13-14 (Mischel et al., 2003) . Expression profiling and genetic analyses of high-grade gliomas have also identified novel predictors of prognosis (Backlund et al., 2003; Nutt et al., 2003; Freije et al., 2004; Liang et al., 2005) .
PDGF and PDGF receptors are commonly coexpressed in high-grade gliomas, suggesting that autocrine PDGF receptor stimulation may contribute to their growth (Hermanson et al., 1992; Westermark et al., 1995) . This notion has experimental support. Gliomalike tumors can be induced in mice after overproduction of PDGF in mouse brain (Uhrbom et al., 1998; Dai et al., 2001) . Also, some glioma-derived cell lines have been blocked by interference with PDGF receptor signaling (Shamah et al., 1993; Strawn et al., 1994; Kilic et al., 2000) .
The interest in PDGF receptors as cancer drug targets has increased with the availability of clinically useful PDGF antagonists like imatinib/Glivec/Gleevec/STI571 (Pietras et al., 2003) . Imatinib is an orally available tyrosine kinase inhibitor, which, in addition to PDGF receptors, also inhibits c-Kit, c-Abl, Bcr-Abl and Arg (reviewed in Capdeville et al., 2002) . The clinical potency of imatinib is well demonstrated in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), which are driven by activated forms of Bcr-Abl and c-Kit or PDGF a-receptor, respectively. Positive effects of imatinib-mediated PDGF receptor inhibition have also been demonstrated by case studies in CML, dermatofibrosarcoma protuberans, hyper-eosinophilic syndrome and GIST (reviewed in Ostman, 2004) .
Effective development of targeted cancer therapy is strongly dependent on proper matching between drug and tumor subsets dependent on the activity of a particular target (Sawyers, 2004) . In the case of CML and GIST, this was achieved through knowledge of an association of these diseases and activated Bcr-Abl and c-Kit, respectively (Druker et al., 2001; Demetri et al., 2002) . Proper patient subsets for targeted therapy have also been identified by analyses of responders and non-responders in heterogeneous cancer patient populations, as demonstrated by the description of a lung cancer subset, characterized by EGFR mutations and sensitivity to EGFR inhibitors (Johnson and Janne, 2005) . Similarly, analyses of sensitivity of glioblastoma patients to EGFR inhibitors have provided indications that expression of mutated EGFR and retention of PTEN predispose to response to treatment (HaasKogan et al., 2005; Mellinghoff et al., 2005) .
Clinical evaluation of the efficacy of imatinib for treatment of gliomas has been initiated. Preliminary findings indicate responses in some patients, particularly after combination treatment with imatinib and hydroxyurea (Dresemann, 2005; Reardon et al., 2005) . These encouraging findings highlight the importance of further defining the characteristics of imatinib sensitivity. In this study, we have analysed a panel of high-grade glioma cultures with regard to imatinib sensitivity and combined these results with biochemical analyses of PDGF receptor status and array-based gene expression profiling. The resulting definition of a novel imatinib-sensitive subset should improve the possibilities for efficient development of PDGF receptor inhibitors for treatment of brain tumors.
Results
Characterization of imatinib sensitivity of human glioma cultures Primary cultures were established from 20 independent high-grade gliomas obtained from surgery. The characteristics of the patients are detailed in Supplementary Table 1. All cases were histopathologically confirmed as high-grade gliomas. Tumors were derived from seven female and 13 male patients with an average age of 58 years.
Cultures were initially characterized with regard to growth rate in the presence of 10% fetal calf serum (FCS). The analyses revealed large variation in growth rate among the cultures. Whereas the fastest growing culture displayed an 18-fold increase in cell number, the most slow-growing cultures only showed a 1.2-fold increase in cell number over the 4-day culture period. Fifteen cultures showed at least a doubling in cell number during a 4-day culture period (Figure 1a ).
Growth inhibition induced by imatinib treatment was analysed on these 15 cultures by comparing the difference in increase of cell number after 4 days of growth in the presence or absence of imatinib (Figure 1b) . Cultures 5, 18, 21, 30, 34, 35 and 38 all displayed less than 20% growth inhibition. In contrast, the growth of cultures 6, 7, 9, 11, 31 and 45 was reduced more than 40%. Cultures 8 and 13 exhibited an intermediate response of 20-40% growth inhibition. The correlation between imatinib sensitivity and growth rate was calculated and indicated a trend toward higher imatinib sensitivity among slow-growing cultures ( Figure 1c) . A selected group of cultures, composed of both imatinib responders and non-responders, were also analysed with regard to sensitivity to AG1296, another tyrosine kinase inhibitor that also blocks PDGF receptors and c-Kit, but not c-Abl (Kovalenko et al., 1994) . The sensitivity profile of the selected cultures was very similar for the two tyrosine kinase inhibitors (Figure 1d ).
To further characterize the growth inhibitory effect of imatinib, cultures 31 and 7, which showed growth inhibition after treatment, were analysed with regard to apoptosis and proliferation (Figure 1e and f). In culture 31, which showed an 85% growth inhibition (Figure 1b ), significant increase in apoptosis occurred concomitant with a significant reduction in proliferation. Culture 7, which displayed 55% growth inhibition, showed similar tendencies (Figure 1e and f).
Platelet-derived growth factor receptor expression and activation in the glioma cultures and correlation with imatinib sensitivity We hypothesized that PDGF receptors were the targets mediating imatinib-induced growth inhibition, and therefore analysed PDGF receptor expression and activation and correlated these parameters with growth inhibition (Figures 2 and 3) . PDGF receptor activation and expression in 18 out of the 20 cultures was analysed by immunoblotting of a receptor-enriched glycoprotein fraction obtained through precipitation with wheat germ agglutinin (WGA)-Sepharose. As positive controls, ligand-stimulated or unstimulated porcine aortic endothelial cells transfected with PDGF a-or b-receptors were used (Figure 2a ). More than 100-fold variation was observed in PDGF a-and b-receptor expression between the glioma cultures (Figure 2b and c) . Overall, the levels of total receptor phosphorylation paralleled the total receptor expression, and thus indicated that the cultures displayed similar levels of phosphorylation per receptor (Figure 2d ). Analyses of receptor phosphorylation confirmed that the dose of imatinib used in the growth inhibition experiments was associated with a reduction in PDGF receptor phosphorylation (Figure 2e ).
The results from correlations of these data with the imatinib sensitivity are shown in Figure 3 . All four PDGF receptor-related parameters analysed showed significant correlations with imatinib sensitivity. Thus, these analyses revealed a broad variation with regard to PDGF receptor expression within the panel of highgrade glioma cultures, and also revealed significant correlation between PDGF receptor expression and imatinib sensitivity and between PDGF receptor phosphorylation and imatinib sensitivity.
Activation status of ERK and Akt in the absence or presence of imatinib ERK and Akt are important mediators of PDGF receptor signaling. The activation status of these kinases was determined in four responders (cultures 6, 7, 9 and 31; see Figure 1b ), five non-responders (cultures 5, 18, 21, 35 and 38; see Figure 1b ) and one intermediate responder (culture 13; see Figure 1b ). Analyses were performed on untreated and imatinib-treated cells.
Activation status of ERK and Akt did not significantly correlate with PDGF receptor expression, PDGF receptor activation or imatinib sensitivity (Supplementary Figure 1 ). Also, no significant correlations were observed between imatinib-induced alterations in Akt phosphorylation and imatinib responsiveness or PDGF receptor status (Supplementary Figure 2d) . However, imatinib sensitivity showed a tendency to be associated with an imatinib-induced reduction in ERK phosphorylation (r ¼ À0.52, P ¼ 0.13, Pearson's correlation) (Supplementary Figure 2b) .
Identification of CXCL12 expression as a marker for imatinib responsiveness
To further characterize the 20 cultures and to obtain additional markers for imatinib sensitivity, gene expression profiling was performed. Results were initially analysed by unsupervised hierarchical clustering using 206 differentially expressed features. Three major clusters, A, B and C, composed of 6, 7 and 7 cultures, Imatinib response in high-grade glioma cultures D Hägerstrand et al respectively, were identified (Figure 4) . The imatinib non-responders and responders showed a trend of being non-randomly distributed across the clusters when comparing clusters A, B and C. For example, 4/7 non-responders belonged to cluster A, whereas 0/6 responders were part of this cluster (P ¼ 0.084, w 2 ). Moreover, the slow-growing group of cultures showed a significant enrichment in cluster C, which contained 4/4 cultures of this category (Po0.05, w 2 ). The indications that correlations existed between gene expression pattern and imatinib responsiveness encouraged supervised analysis. For this purpose, the 10 cultures that yielded the clearest results from the analyses of imatinib sensitivity were used to identify the expression patterns best correlating with imatinib responsiveness. Analysis was first performed using the method of weighted voting (Golub et al., 1999) , including a leave-one-out validation. When 2-40 features were used for classification, all 10 cultures were correctly classified in the leave-one-out validation (Supplementary Figure 3) . Subsequently, the SAM method of Tusher et al. was also used to identify genes that were differentially expressed between responders and non-responders (see Materials and methods for details). The two methods produced very similar results with regard to identification of differentially expressed genes. Both methods identified CXCL12/SDF-1 as the most differentially expressed gene. Furthermore, among the top 10 ranked features, six appeared in both two lists (Table 1) .
The relative CXCL12 expression, as derived from the microarray analyses, in the 13 cultures with high or low imatinib response is shown in Figure 5a , together with the data from the analyses of imatinib sensitivity. As can be seen, all six responders showed a higher CXCL12 expression than any of the seven non-responders
PDGFRβ (958) Phospho-Tyr (PY99) (Figure 5b ).
In agreement with the array-based data, a positive correlation was observed between CXCL12 expression and imatinib sensitivity as determined by qRT-PCR (r ¼ 0.60, Po0.05 Pearson's correlation) (Figure 5c ). This difference was also found to be statistically significant when CXCL12 expression in responders and non-responders was analysed by t-test (Po0.05). Together, these analyses thus identify the level of CXCL12 expression as a strong marker for imatinib responsiveness.
Treatment with exogenous CXCL12 converts imatinib non-responsive high-grade glioma cultures to imatinibresponsive cultures Two cell cultures, 21 and 35, which were defined as nonresponsive to imatinib (Figure 1b) , and also displayed low CXCL12 expression, were selected to investigate a possible functional relationship between CXCL12 and imatinib sensitivity. In agreement with previous results, imatinib alone did not induce any significant growth inhibition, whereas treatment with CXCL12 showed growth inhibitory effects (Figure 5d ). Interestingly, cotreatment of imatinib and CXCL12 induced a significantly stronger growth inhibitory effect than CXCL12 alone in culture 21, with a similar tendency observed in culture 35 (Figure 5d ).
This finding suggests that stimulation with CXCL12 alters the cellular phenotype in a manner that makes cells more sensitive to imatinib treatment.
CXCL12 and platelet-derived growth factor a-receptors are coexpressed in human glioblastoma tissue samples The characterization of the cultures thus indicated the existence of an imatinib-sensitive high-grade glioma subset characterized by high PDGF receptor expression and high CXCL12 expression. To obtain information about the in vivo significance of these findings, we analysed a publicly available expression data set of human glioblastoma biopsies (Nutt et al., 2003) . The data set, derived from 14 glioblastoma biopsies and reporting the expression of more than 12 000 features, was interrogated to identify genes with an expression pattern that correlated with the expression levels of CXCL12. Whereas expression data for the PDGF b-receptor could not be found in this data set, the PDGF a-receptor showed the 48th highest correlation with CXCL12 expression (r ¼ 0.79, Po0.001 Pearson's correlation). Results, including r-values and significance, are shown for all the 15 cultures for which data on imatinib sensitivity were obtained.
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This analysis thus indicates the existence also of a previously unrecognized clinical subset of high-grade gliomas, characterized by high expression of CXCL12 and PDGF receptor.
Discussion
Our analyses of a panel of primary cultures derived from high-grade gliomas have defined a novel imatinibsensitive subset (Figure 1 ), which is characterized by high PDGF receptor expression and activation ( Figures  2 and 3) , a particular gene expression pattern (Figure 4 ) and high levels of CXCL12 expression ( Figure 5 ).
Imatinib-sensitive cultures were characterized by high PDGF receptor expression, indicating that high PDGF receptor expression is a marker for a growth dependence of PDGF receptor signaling. Whether the large variations in receptor expression are caused by variable extent of PDGF receptor amplification or by differences at the transcriptional or translational levels remains presently unresolved. During immunoblotting analyses of PDGF receptor expression, receptors appeared at the expected migratory positions (data not shown). The analyses thus did not provide any evidence for the occurrence of mutations in the receptors leading to major structural alterations. Concerning the possibility of activating point mutations in PDGF receptors, we note that there was overall a very good correlation between receptor amounts and receptor phosphorylation, arguing against the occurrence of PDGF receptors activated by mutation. In this context, it is also noteworthy that recent sequencing of exons 11 and 17 of the PDGF a-receptor in eight cases of glioblastoma failed to detect any mutations (Sihto et al., 2005) .
The variable growth rates of the cultures present some intrinsic differences in characterizing the response. In this study, reduction in growth after 4 days of culture with imatinib was used to determine sensitivity, and 100% growth inhibition is defined as an effect that leads to same cell number at the start and end of the 4-day period. This might bias the results toward greater effects on slow-growing cultures. A trend toward higher responsiveness among slow-growing cultures was also indeed noted. However, it is also noted that the responder and non-responder groups were composed of a mixture of slow-and fast-growing cultures. The notion that slow-growing cultures respond better will ultimately be tested in clinical trials where the responsiveness of tumors with more or less aggressive clinical course can be compared.
Issues of selection of cell subsets, and adoption to in vitro conditions, are intrinsic problems when performing studies on tumor-derived cells grown in tissue culture. However, a number of points suggest that our findings are also relevant for the tumors from which the cultures were derived. Firstly, as large variations in PDGF receptor expression were observed between the cultures, it is unlikely that the culture conditions per se, which were identical for all cultures, had a major impact on the levels of PDGF receptor expression. Thus, the variation is likely to reflect intrinsic properties of the different tumor cells. The same reasoning applies to the variable CXCL12 expression. Secondly, both CXCL12 Figure 4 Unsupervised hierarchical clustering of cultures yields subsets with non-random distribution of imatinib responders and non responders. Clustering analyses was performed on all 20 cultures. Indicated growth rate reflects fold increase in cell number after 4 days in culture. Imatinib response is indicated with þ (more than 40% growth inhibition), À (less than 20% growth inhibition) and * (20-40% growth inhibition). The features showing the highest differential expression in responders and non-responders were identified by the methods of Tusher et al.
(top list) and Golub et al. (bottom list) . Both methods identified CXCL12 as the most differentially expressed gene. Among the top six features identified with the two methods, five were in common.
Imatinib response in high-grade glioma cultures D Hägerstrand et al and PDGF receptors have been shown to display very different levels of expression in different glioma tumors (Hermansson et al., 1988 (Hermansson et al., , 1992 Rempel et al., 2000) . Finally, and most importantly, the observation that expression of PDGF a-receptors and CXCL12 was also correlated in glioblastoma tumor tissues further supports the notion that the phenotype described by our studies is clinically relevant. Characterization of glioma tissue has indicated that a significant fraction of cases display EGF receptor amplification (Libermann et al., 1985) . Observations from experimental studies with different types of EGF receptor inhibitors have also supported initiation of early clinical trials with EGF receptor antagonists for treatment of gliomas (Heimberger et al., 2002; Rich et al., 2004) . Continued characterization of the panel of glioma cultures analysed in the present study might indicate how cases with high and low EGF receptor expression are distributed among the subsets of imatinib responders and non-responders, as well as between the different expression profile-based clusters.
This study was guided by the hypothesis that PDGF receptors are the relevant targets for imatinib in high-grade gliomas. The strong correlation between PDGF receptor status and imatinib sensitivity supports this notion. Also, data on c-Kit and c-Abl expression, as determined from the microarray analyses of the 15 cultures for which imatinib sensitivity was determined, did not provide any evidence for correlations between levels of these target molecules and imatinib sensitivity (data not shown). Furthermore, the similarities in responsiveness to imatinib and AG1296 also make it very unlikely that inhibition of c-Abl contributes significantly to the differential sensitivity to imatinib treatment of the cultures. We therefore conclude that in these cells PDGF receptors are the major targets mediating the growth inhibitory effects of imatinib.
Growth inhibition after imatinib treatment of different tumor models has been assigned to either antiproliferative or proapoptotic effects (Kilic et al., 2000; Sjoblom et al., 2001) . In our study, we could detect a proapoptotic effect of imatinib, which occurred concomitantly with a reduction in proliferation ( Figure  1e and f) . Concerning the signaling pathways that mediate these effects, it is noted that reduction in neither phospho-ERK nor phospho-Akt correlated with growth inhibitory effects. However, these analyses were performed after culturing of cells in 10% FCS and it is thus possible that relevant inhibitory effects of subsets of the ERK or Akt pools failed to be revealed. In this context, it is also noteworthy that no correlation was observed in our study between imatinib sensitivity and basal phospho-Akt levels. These findings give preliminary indications that the markers among glioblastoma for Imatinib response in high-grade glioma cultures D Hägerstrand et al sensitivity to EGF receptor and PDGF receptor inhibitors will vary, as recent studies indicate a strong relationship between phospho-Akt status and response to erlotinib .
The correlation between the global gene expression pattern and imatinib sensitivity, as indicated by the unsupervised clustering analyses, is compatible with the notion that this glioma cell subset is derived from a distinct precursor cell population. Continued comparative analyses of these expression profiles with novel data sets from defined neuronal and glial precursor populations will further shed light on this issue. In this context, it will also be interesting to analyse if any of the three clusters, identified in the unsupervised analyses, display properties similar to some of the recently described brain tumor stem cells (Singh et al., 2003 (Singh et al., , 2004 Galli et al., 2004; Yuan et al., 2004) .
The supervised analyses revealed a striking and unexpected correlation between CXCL12 expression and imatinib sensitivity. Furthermore, exogenous stimulation with CXCL12 conferred some imatinib sensitivity to cultures that did not show an intrinsic sensitivity to imatinib. This latter finding suggests a novel functional relationship between PDGF receptor signaling and signaling triggered by CXCR4, the receptor for CXCL12. Possible explanations of this finding include a CXCL12-induced general re-programming of cells rendering them more imatinib sensitive, or more direct crosstalk between CXCR4 signaling and PDGF receptors. Concerning the latter possibility, it is noteworthy that CXCR4 transactivation of EGF receptors has recently been described (Cabioglu et al., 2005; Porcile et al., 2005) . Obviously, these topics merit further investigations.
In conclusion, we have identified and defined the characteristics of a previously unrecognized subset of glioma-derived cell cultures by combining cell biological, biochemical and expression profiling approaches. The identification of this subset, characterized by imatinib sensitivity, high PDGF receptor expression and high expression of CXCL12, has immediate impact upon the design and evaluation of upcoming trials with imatinib, or other PDGF receptor antagonists, for treatment of malignant brain tumors. Furthermore, the observations suggest a previously unrecognized functional relationship between signaling induced by PDGF receptor and CXCR4, which merits continued exploration.
Materials and methods
Establishment of cell cultures and analysis of growth rate and sensitivity to imatinib Tumor samples were obtained by open surgery from patients with radiologically suspect high-grade glioma lesions at the Department of Neurosurgery, Uppsala University Hospital in accordance with a permit from the local Research Ethics Committee (UpS98415). All tumors were histopathologically analysed by a neuropathologist and diagnosed as high-grade gliomas (WHO grade 2-3, grade 3, grade 2-4, grade 3-4 or grade 4) (see Supplementary Table 1 for details). Tumors were derived from 13 males and seven females, with an average age of 58 years. Some of the cases had adjacent low-grade glioma areas in the surgical samples, but none was clinically defined as secondary glioblastoma.
Primary cultures were established from tumors according to standard procedures (Ponten and Westermark, 1978) . For initial analyses of growth rate, cells from the different cultures were seeded in duplicate, in medium with 10% FCS, in 24-well plates (Sarstedt, Nu¨mbrecht, DE) . The numbers of cells were counted on days 1 and 5 and growth rate was expressed as fold increase in cell number during the culture period.
The 15 cell cultures that displayed more than twofold increase in cell number during the 4 days of culture were analysed with regard to the effects of imatinib on cell growth. Cells were seeded at a density of 4000 cells per well in 96-well plates (Sarstedt). After 1 day of culture, media were exchanged to media with or without 1 mM imatinib (provided by Novartis, Basel, CH), 3 mM AG1296 (Calbiochem, LaJolla, CA, USA) or 75 ng/ml CXCL12/SDF-1-a (PeproTech, London, GB). After 4 days of incubation, including media and drug change after 2 days, cells were fixed for 30 min in cold 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) and stained for 30 min with 0.01% crystal violet in 4% ethanol. Samples were washed three times with distilled water, and air dried for at least 30 min. Stained cells were dissolved in 100 ml 1% SDS and absorbance was quantified with a Biomek 1000 optical tool (Beckman, Fullerton, LA, USA) at 600 nm. Imatinib response was expressed as % reduction of increase in cell number during the 4-day period of treatment.
For analysis of apoptosis, cells were seeded at a density of 20 000 cells per well in 24-well plates. A total of 10 000 cells per well in 96-well plates were seeded for the proliferation assay. After 1 day of culture, media were exchanged to media with or without 1 mM imatinib. Treatment with 50 mM etoposide was used as a positive control in the apoptosis assay. Proliferation was measured after 1 day of incubation with drugs by incubating cells with 5-bromo-2 0 -deoxy-uridine (BrdU) for 6 h followed by analysis of BrdU incorporation with the 5-bromo-2 0 -deoxy-uridine labeling and detection kit III (Roche, Basel, CH). Apoptosis was measured after 2 days of incubation with drugs, by detection of cytoplasmic monoand oligonucleosomes with the cell death detection ELISA plus kit (Roche).
Platelet-derived growth factor receptor status Cell lysates from approximately 500 000 cells, derived from subconfluent cultures kept in medium supplemented with 10% FCS, were prepared. Glycoproteins were enriched from total cell lysates by precipitation with WGA-Sepharose (Amersham Pharmacia Biotech, Uppsala, SE), as described . In parallel, control samples were prepared from unstimulated or PDGF-BB-stimulated porcine aortic endothelial (PAE) cells stably expressing PDGF a-receptor (PAE/ PDGFRa) or PDGF b-receptor (PAE/PDGFRb). Samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using 7% polyacrylamide gels and transferred to hybond-C-extra membranes (Amersham Life Science, Uppsala, SE). Receptor immunoblotting was performed with PDGFRb antibody (1 mg/ml 958 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA)), PDGFRa antibody (1 mg/ml 338 (Santa Cruz Biotechnologies)) and phosphotyrosine-specific antibody (1 mg/ml PY99 (Santa Cruz Biotechnologies)), as described . For analyses of PDGF receptor phosphorylation after ligand stimulation, cultures were incubated with 100 ng/ml of PDGF-BB for 5 min. Similarly,
